Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Jc Virus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43895   clinical trials with a EudraCT protocol, of which   7301   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Jc Virus. Displaying page 1 of 1.
    EudraCT Number: 2019-002566-13 Sponsor Protocol Number: NEXT-MS Start Date*: 2019-12-19
    Sponsor Name:Amsterdam University Medical Center
    Full Title: Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10070425 Multiple sclerosis exacerbation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000725-41 Sponsor Protocol Number: CLI-107-15 Start Date*: 2013-01-22
    Sponsor Name:Cytheris S.A.
    Full Title: A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy.
    Medical condition: HIV-infected patients with Progressive Multifocal Leukoencephalopathy
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10036807 Progressive multifocal leukoencephalopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000763-45 Sponsor Protocol Number: P-105-401 Start Date*: 2022-07-25
    Sponsor Name:AlloVir, Inc.
    Full Title: Global Registry for Long-Term Follow-up of Patients Participating in Clinical Trials with Posoleucel (ALVR105)
    Medical condition: Adenovirus (AdV), BK virus (BKV), John Cunningham virus (JCV), human herpesvirus 6 (HHV- 6), Epstein-Barr virus (EBV), and cytomegalovirus (CMV) infections and/or disease in patients at high risk f...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    20.1 10021881 - Infections and infestations 10055181 BK virus infection PT
    22.0 10021881 - Infections and infestations 10020431 Human herpesvirus 6 infection PT
    21.1 10021881 - Infections and infestations 10015108 Epstein-Barr virus infection PT
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    21.1 10021881 - Infections and infestations 10023163 JC virus infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Ongoing) SE (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005105-27 Sponsor Protocol Number: P-105-202 Start Date*: 2022-05-02
    Sponsor Name:AlloVir, Inc.
    Full Title: Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV...
    Medical condition: Adenovirus (AdV), BK virus (BKV), John Cunningham virus (JCV), human herpesvirus 6 (HHV- 6), Epstein-Barr virus (EBV), and cytomegalovirus (CMV) infections and/or disease in patients at high risk f...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    20.1 10021881 - Infections and infestations 10055181 BK virus infection PT
    22.0 10021881 - Infections and infestations 10020431 Human herpesvirus 6 infection PT
    21.1 10021881 - Infections and infestations 10015108 Epstein-Barr virus infection PT
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    21.1 10021881 - Infections and infestations 10023163 JC virus infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002204-33 Sponsor Protocol Number: C32322 Start Date*: 2007-03-02
    Sponsor Name:UCB Pharma S.A.
    Full Title: Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two dose...
    Medical condition: Relapsing forms of multiple slerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048393 Multiple sclerosis relapse LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FI (Prematurely Ended) HU (Completed) SE (Prematurely Ended) GB (Completed) ES (Completed) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-007057-42 Sponsor Protocol Number: A4M108119 Start Date*: 2007-05-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast
    Medical condition: relapsing forms of multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    9.1 10063400 Secondary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-004040-30 Sponsor Protocol Number: EOC.NSI.11.01 Start Date*: 2013-05-24
    Sponsor Name:Ospedale Regionale di Lugano
    Full Title: Natalizumab de-escalation to interferon-beta-1b in patients with relapsing-remitting multiple sclerosis: A multicenter study
    Medical condition: relapse-remitting multiple sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003877-91 Sponsor Protocol Number: TOLERA Start Date*: 2019-06-13
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Sequential B cell/T cell therapy to re-induce humoral immune tolerance in ACPA-positive Rheumatoid Arthritis (TOLERA): a prospective randomized controlled open-label single-centre clinical trial in...
    Medical condition: Active rheumatoid arthritis with ACPA antibodies failing methotrexate
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004061-41 Sponsor Protocol Number: 101-MS-321 Start Date*: 2006-06-01
    Sponsor Name:BIOGEN IDEC LTD
    Full Title: An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o...
    Medical condition: Multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) FI (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 17:50:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA